

## Conference on P53 strategies for fighting cancer

Source: *Bharatbook*

Dated: *Sep 02, 2008*

20th - 21st November 2008, BSG Conference Centre, 226 - 236 City Road, London, EC1V 2TT, United Kingdom

Conference on P53 strategies for fighting cancer

Follow the guardian angel of the genome from cutting edge research to large scale patient care  
20th - 21st November 2008, BSG Conference Centre, 226 - 236 City Road, London, EC1V 2TT, United Kingdom

According to the WHO, Cancer is a leading cause of death worldwide accounting for 13% of all deaths. There are several strategies for prevention, control and treatment of cancer, but there is still a long way to go before cancer is no longer a life threatening disease.

Cancer therapies are still often quite blunt weapons, used against a diversified enemy. In the future, cancer therapies will be more versatile, more specific, and the development of those strategies is of great interest to everyone.

Something that more than half of all human tumors have in common is a defective p53, making this protein a desirable target for the next generation of cancer therapeutics. By ensuring that cancer cells produce the wild type p53, many tumors could stop growing or simply be eliminated.

To encourage the efforts to bring more specific cancer therapies into use, Visiongain's p53 strategies to fight cancer conference will focus on how to bring p53 related therapeutics into large scale patient care.

The conference will cover themes such as:

- The role of p53 in upcoming cancer therapeutics
- Models for identification of drug targets applicable to p53
- Influencing the p53 activation cascade
- How to introduce p53 therapeutics into large scale patient care

Key Speakers

- Zehan Chen, Research Investigator, Cancer Research, Abbott Laboratories
- Maxwell Cummings, Senior Scientist in Molecular Design and Informatics, Johnson & Johnson
- David Lane, Director of the Cancer Research UK Transformation Research Group, University of Dundee
- Brian Lovatt, CEO, Vision Healthcare & Oncology Know
- Allan Fersht, Director, MRC Centre for Protein Engineering
- Wolfgang Deppert, Professor, Heinrich-Pette Institute
- Jola Gore-Booth, Chief Executive, Europacolon
- Klas Wiman, Professor, Molecular Cell and Tumour Biology, Karolinska Institutet
- Lydie Sparfel, UMR-INSERM U620, Faculté de Pharmacie, University of Rennes
- Stefano Marullo, Director of Research, Department of Cellular Biology, Institut Cochin
- Hilary Calvert, Professor of Medical Oncology, University of Newcastle

Who will be there?

VPs Directors, Heads, and Managers in:

- Cancer research
- Pharmaceutical Research and Development
- Oncology
- Drug Discovery
- Medicinal Chemistry
- Production Planning
- Immunology
- Regulatory Affairs
- Pricing and marketing
- Early development
- Clinical Science

Day 1

09:30 Registration and refreshments

10:00 Opening address from the chair

Jola Gore-Booth  
Chief Executive  
Europacolon

10:10 The future role of p53 in cancer therapy

- P53 research in a therapeutic perspective
- The direction of the p53 research and how to improve the therapeutic value of the research
- The future: what is the goal?

Iman El-Hariry  
Group Director  
Oncology MDC  
Europe  
GlaxoSmithKline\*

10:50 The key to develop a successful product in cancer therapy

- Which population and indication
- Which endpoints
- Pricing and reimbursement strategy the key driver

Brian Lovatt  
CEO  
Vision Healthcare & Oncology Know

11:30 Morning refreshments

11:50 Drug discovery in the p53 pathway using phenotypic screens

- Phenotypic screens offers the unique possibility to analyse entire genomes
- The screening can be successfully applied to the identification of drug targets
- A valuable tool for future target discovery efforts

David Lane

Director of the Cancer Research UK Transformation Research Group  
University of Dundee

12:30 Targeted rescue of oncogenic mutants of p53

- Mutation Y220C causes temperature-sensitive global unfolding
- In-Silico design gives leads to fill the induced cavity
- Suitable leads re-stabilise Y220C for crystal structures give improved design and fine biological testing

Alan Fersht  
Director  
MRC Centre for Protein Engineering

13:10 Networking lunch

14:30 Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics

- Chk1 is the key mediator for DNA damage checkpoint in p53 deficient cells
- Chk1-mediated cell cycle arrest provides an escape mechanism to conventional cancer therapeutics
- Inhibition of Chk1 abrogates DNA damage checkpoints in p53 deficient cancer cells but not p53 proficient cells
- Chk1 inhibitor selectively enhances drug-induced apoptosis in p53 deficient cancer cells

Zehan Chen  
Research Investigator, Cancer Research  
Abbott Laboratories

For more information kindly visit: <http://www.bharatbook.com/seminars/Conference-on-P53-strategies-for-fighting-cancer.htm>

Category	Medical
Tags	strategies, fighting, cancer, Research, conference, seminar
Email	<a href="#">Click to contact author</a>
Phone	+912227578668
Fax	+912227579131
Address	207 Hermes Atrium, Sector 11 CBD Belapur Navi Mumbai
City/Town	Navi Mumbai
State/Province	Maharashtra
Zip	400614
Country	India
Link	<a href="http://prlog.org/10112522">http://prlog.org/10112522</a>



Scan this QR Code with your SmartPhone to-

- \* Read this news online
- \* Contact author
- \* Bookmark or share online